Propofol Versus the Use of Dexmedetomidine as a Sedative Agent for Colonosopy

Tanta University

Status and phase: Unknown; Phase 3

Conditions: Colonic Diseases

Treatments: Drug: Propofol; Drug: Dexmedetomidine

Study type: Interventional

Funder types: Other

Identifiers

NCT03466632

dexmedetomidine colonoscopy

Details and patient eligibility

About

Dexmedetomidine as a Sedative Agent for Patients Presented for Lower Gastrointestinal Endoscopy

Full description

Propofol Versus the Use of Dexmedetomidine as a Sedative Agent for Patients Presented for Lower Gastrointestinal Endoscopy

Enrollment: 100 estimated patients

Sex: All

Ages: 25 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• aged 25-45 years,
• ASA class I or II,
• who are scheduled for elective outpatient colonoscopy

Exclusion criteria

• refused to give informed consent
• if they had known hypersensitivity to the used drugs
• patients with morbidly obese patients
• patients with increased risk for airway obstruction as obstructive sleep apnea,
• Liver diseases

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

100 participants in 2 patient groups

• Propofol Group

Active Comparator group

Description:

propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure..

Treatment:

Drug: Propofol

• Dexmedetomidine Group

Active Comparator group

Description:

dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure

Treatment:

Drug: Dexmedetomidine